肝细胞癌中磷脂酰肌醇蛋白聚糖-3的表达及其临床意义

肝脏 ›› 2022, Vol. 27 ›› Issue (11): 1180-1182.

肝细胞癌中磷脂酰肌醇蛋白聚糖-3的表达及其临床意义

赵桓玉, 张瑞瑞, 张正卫, 吴建, 孙苏安

223399 江苏南京医科大学附属淮安第一医院病理科

收稿日期:2022-05-07 出版日期:2022-11-30 发布日期:2023-01-31
通讯作者: 张瑞瑞,Email:1204047004@qq.com
基金资助:
淮安市自然科学研究计划基金(HABZ202107)

Expression and prognostic significance of GPC-3 protein in hepatocellular carcinoma

ZHAO Huan-yu, ZHANG Rui-rui, ZHANG Zheng-wei, WU Jian, SUN Su-an

Department of Pathology, Huai'an First Hospital Affiliated to Nanjing Medical University, Jiangsu 223399, China

Received:2022-05-07 Online:2022-11-30 Published:2023-01-31
Contact: ZHANG Rui-rui,Email:1204047004@qq.com

摘要/Abstract

摘要： 目的探讨磷脂酰肌醇蛋白聚糖-3(glypican-3,GPC-3)蛋白与HCC的相关性。方法选择2014年1月至2015年4月HCC患者91例。取91份肝癌组织和32份癌旁正常肝组织,采用免疫组织化学SP间接法检测GPC-3蛋白及P53蛋白的表达水平,并对其进行相关性分析和预后评价。结果 91份肝癌组织中,73份(80.2%)GPC-3细胞染色阳性;32份癌旁肝组织中,2份(6.3%)GPC-3细胞染色阳性,差异有统计学意义(P<0.01)。HCC患者GPC-3阳性组P53阳性率为92.5%,P53阴性率为70.6%(P=0.015)。GPC-3蛋白表达与HCC的组织学分级及TNM分期有相关性(P=0.010、0.011),GPC-3阳性组患者的生存率为9.6%,低于GPC-3阴性组38.9%(P=0.017)。结论 GPC-3是诊断HCC的重要标志物,P53与GPC-3表达在肿瘤发生发展过程中可能存在相关通路,GPC-3的表达模式有助于判断HCC的预后。

关键词: 肝癌, 肝细胞性肝癌, GPC-3, 免疫组织化学法, P53, 预后

Abstract: Objective To investigate the expression and clinical significance of glypican-3 (GPC-3) protein in hepatocellular carcinoma (HCC) and to investigate the correlation between the GPC-3 expression and the prognosis of HCC.Methods Ninety-one HCC cases and 32 healthy subjects from January 2014 to April 2015 were collected. The GPC-3 and P53 protein levels of all subjects were detected through immunohistochemical SP indirect method. The correlation and prognostic value between HCC and proteins were analyzed.Results The GPC-3 expressed in 80.2% HCC tissues (73/91) and 6.3% (2/32) normal tissues, the difference was. statistically significant (P<0.001). The positive rate P53 (92.5%) was significantly higher in GPC-3 positive group (P=0.015). The positive expression of GPC-3 was related to the histological differentiation and TNM stages (P=0.010, P=0.011). The survival rate of patients in GPC-3 positive group (9.6%) was much lower than that in GPC-3 negative group (38.9%) (P=0.017).Conclusion GPC-3 is an important biomarker in diagnosing HCC. P53 and GPC-3 pathway may be related to tumorigenesis and progression of HCC. Detection of the GPC-3 expression is important in evaluating the prognosis of HCC.

Key words: Liver neoplasm, Hepatocellular carcinoma, Glypican-3, Immunohistochemistry, P53, Prognosis

赵桓玉, 张瑞瑞, 张正卫, 吴建, 孙苏安. 肝细胞癌中磷脂酰肌醇蛋白聚糖-3的表达及其临床意义[J]. 肝脏, 2022, 27(11): 1180-1182.

ZHAO Huan-yu, ZHANG Rui-rui, ZHANG Zheng-wei, WU Jian, SUN Su-an. Expression and prognostic significance of GPC-3 protein in hepatocellular carcinoma[J]. Chinese Hepatolgy, 2022, 27(11): 1180-1182.

参考文献

[1] Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol, 2016, 22:275-283.
[2] Yao M, Yao DF, Bian YZ, et al. Oncofetal antigen glypican-3 as a promisingearly diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int,2011,10:289-294.
[3] Yao M, Yao DF, Bian YZ, et al. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobliary Pancreat Dis Int, 2013, 12: 171-179.
[4] Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology,2010,53:39- 43.
[5] 卞银珠,姚登福,张崇国,等.磷脂酰肌醇蛋白聚糖-3的表达特征及其在肝癌诊断与鉴别诊断中的价值.中华肝脏病杂志,2011,19:260-265.
[9] 高建芝,杜经丽,李佳,等. VEGF相关信号通路在肝癌组织中的表达及临床意义.临床与实验病理学杂志,2014,30:75-78.
[10] 霍莉莉,李慧,魏枫,等. 乳腺癌中P53的表达与上皮-间充质转化的相关性及其临床意义.中国肿瘤临床,2014,41:776-780.
[11] Wallacel MC,Preen D, Jeffrey GP, et al. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gasrtoenterol Hepatol, 2015, 9:765-779.
[12] Aviel-Ronen S, Lau SK, Pintilie M, et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol, 2008, 2l: 817-825.
[13] Shirakawa H, Kuronuma T, Nishimura Y, etal. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol, 2009, 34:649-656.
[14] Di Tommaso L, Franchi G, Park YN, et al.Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.Hepatology, 2007, 45:725-734.
[15] Capurro MI, Xiang YY, Lobe C, et al.Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.CancerRes, 2005,65(14):6245-6254.

[1]	胡维杰, 陈小萍, 吴荣刚, 马臻雏. T2WI序列图像纹理分析对肝硬化浸润性肝癌和局灶性融合性纤维化的鉴别诊断价值[J]. 肝脏, 2022, 27(9): 986-989.
[2]	柴晓哲, 朱霞峰, 王少峰, 骆成林. 白蛋白-胆红素评分联合血氨检测对原发性肝癌切除术后并发肝性脑病的预测价值[J]. 肝脏, 2022, 27(9): 994-998.
[3]	谢慧, 王亮亮, 江凯, 袁潇. 多层螺旋CT与高场强磁共振LAVA增强对乙型肝炎肝硬化背景小肝癌的诊断价值对比[J]. 肝脏, 2022, 27(8): 895-897.
[4]	张文婷, 徐晓英, 卢蓉. 血清sFlt-1和PlGF联合检测对妊娠期急性脂肪肝病情严重程度和疾病预后的评估价值[J]. 肝脏, 2022, 27(8): 915-919.
[5]	马军伟, 柳计强, 宋冉. IVIM扩散加权成像在氩氦刀冷冻治疗原发性肝癌中的作用[J]. 肝脏, 2022, 27(7): 778-781.
[6]	苏雨, 孙小怡, 王倩怡, 赵新颜, 贾继东. 既往乙型肝炎病毒感染对自身免疫性肝炎治疗应答及预后的影响[J]. 肝脏, 2022, 27(7): 789-794.
[7]	史冬梅, 项晓刚, 赵刚德, 王晓琳. 丙型肝炎相关肝细胞癌的临床特征和预后[J]. 肝脏, 2022, 27(6): 628-633.
[8]	周成香, 刘亚斌, 苏红, 蒋怡香, 林海燕. 肝脏超声造影对原发性肝癌微波消融术后血供状态评估的价值[J]. 肝脏, 2022, 27(6): 637-639.
[9]	刘民强, 查晓亮, 黄湘荣, 吴强, 何仁亮. 肝癌射频消融患者术后中重度疼痛的危险因素分析[J]. 肝脏, 2022, 27(6): 640-643.
[10]	宋文月, 耿承军, 江凯. T2WI序列图像与多期多排螺旋CT扫描对肝硬化患者结节和小肝癌的鉴别诊断价值[J]. 肝脏, 2022, 27(6): 644-646.
[11]	董其刚, 许军. PALBI联合AMIS65评分系统用于肝硬化急性上消化道出血患者预后评估的价值分析[J]. 肝脏, 2022, 27(6): 662-667.
[12]	李爽旗, 蒙连新, 韦素雨, 王焬圣, 季红运, 吴娜. 肝硬化伴与不伴肝源性糖尿病临床表现及预后[J]. 肝脏, 2022, 27(6): 668-671.
[13]	黄鑫昱, 苏盛元, 王开琛, 王甘露. 巨噬细胞在肝癌发生、发展中的作用机制及其靶向治疗研究进展[J]. 肝脏, 2022, 27(6): 708-711.
[14]	苑广菲, 孙悦, 孟方园, 高沿航. 酒精性肝病未被满足的临床需求与挑战[J]. 肝脏, 2022, 27(5): 508-510.
[15]	康玮玮, 田辉, 冯丽丽, 刘立伟, 徐曼曼, 孔明, 段钟平, 邹正升, 陈煜. 慢加急性肝衰竭患者长期生存状况变化及临床特点分析[J]. 肝脏, 2022, 27(5): 516-520.